GIMAP/EA3064, Université de Lyon, CIC 1408 Vaccinology, Saint-Etienne, France.
Institut de Biologie & Chimie des Protéines - LBTI, UMR 5305 - CNRS/University of Lyon, Lyon, France.
J Allergy Clin Immunol. 2016 Jan;137(1):214-222.e2. doi: 10.1016/j.jaci.2015.07.042. Epub 2015 Sep 26.
Transmission of mucosal pathogens relies on their ability to bind to the surfaces of epithelial cells, to cross this thin barrier, and to gain access to target cells and tissues, leading to systemic infection. This implies that pathogen-specific immunity at mucosal sites is critical for the control of infectious agents using these routes to enter the body. Although mucosal delivery would ensure the best onset of protective immunity, most of the candidate vaccines are administered through the parenteral route.
The present study evaluates the feasibility of delivering the chemically bound p24gag (referred to as p24 in the text) HIV antigen through secretory IgA (SIgA) in nasal mucosae in mice.
We show that SIgA interacts specifically with mucosal microfold cells present in the nasal-associated lymphoid tissue. p24-SIgA complexes are quickly taken up in the nasal cavity and selectively engulfed by mucosal dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin-positive dendritic cells. Nasal immunization with p24-SIgA elicits both a strong humoral and cellular immune response against p24 at the systemic and mucosal levels. This ensures effective protection against intranasal challenge with recombinant vaccinia virus encoding p24.
This study represents the first example that underscores the remarkable potential of SIgA to serve as a carrier for a protein antigen in a mucosal vaccine approach targeting the nasal environment.
黏膜病原体的传播依赖于它们结合上皮细胞表面、穿过这一薄屏障并进入靶细胞和组织的能力,从而导致全身感染。这意味着黏膜部位的病原体特异性免疫对于控制通过这些途径进入体内的感染因子至关重要。尽管黏膜传递可确保最佳的保护性免疫起始,但大多数候选疫苗都是通过注射途径给药。
本研究评估通过分泌型免疫球蛋白 A(SIgA)在小鼠鼻黏膜中传递化学结合的 p24gag(本文中称为 p24)HIV 抗原的可行性。
我们表明,SIgA 与鼻相关淋巴组织中存在的黏膜微皱褶细胞特异性相互作用。p24-SIgA 复合物在鼻腔中迅速被摄取,并被黏膜树突状细胞特异性细胞间黏附分子 3 抓取非整合素阳性树突状细胞选择性吞噬。p24-SIgA 鼻内免疫在全身和黏膜水平上均引发针对 p24 的强烈体液和细胞免疫应答。这确保了对鼻腔内用表达 p24 的重组痘苗病毒的有效保护。
本研究首次证明了 SIgA 作为黏膜疫苗方法中针对鼻腔环境的蛋白质抗原载体的显著潜力。